Aldosterone and cortisol affect the risk of sudden cardiac death in haemodialysis patients

European Heart Journal

Volumn 34, Issue 8, 2013, Pages

  Drechsler, Christiane ^a,b   Ritz, Eberhard ^c   Tomaschitz, Andreas ^d   Pilz, Stefan ^d,e   Schönfeld, Stephan ^a   Blouin, Katja ^a   Bidlingmaier, Martin ^f   Hammer, Fabian ^a   Krane, Vera ^a   März, Winfried ^d,g,h   Allolio, Bruno ^a   Fassnacht, Martin ^a   Wanner, Christoph ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d MEDICAL UNIVERSITY OF GRAZ   (Austria)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f UNIVERSITY OF MUNICH   (Germany)

^g SYNLAB ACADEMY   (Germany)

^h UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Aldosterone; Cardiovascular events; Cortisol; Kidney disease; Mortality; Sudden cardiac death

Indexed keywords

ALDOSTERONE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCORTISONE;

ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE HYPERTROPHY; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYDROCORTISONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SUDDEN DEATH;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALDOSTERONE; ANTICHOLESTEREMIC AGENTS; DEATH, SUDDEN, CARDIAC; DRUG SYNERGISM; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROCORTISONE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PYRROLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; YOUNG ADULT;

EID: 84874496055     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehs361     Document Type: Article

References (50)

1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351:1296-1305.
2. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K, Zelenkofske S, Leimberger JD, Califf RM, Pfeffer MA. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004;351: 1285-1295.
3. US Renal Data System. USRDS 2008 Annual Data Report. Bethesda, MD: National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases 2008.
4. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005;353:238-248.
5. Iwashima F, Yoshimoto T, Minami I, Sakurada M, Hirono Y, Hirata Y. Aldosterone induces superoxide generation via Rac1 activation in endothelial cells. Endocrinology 2008;149:1009-1014.
6. Leopold JA, Dam A, Maron BA, Scribner AW, Liao R, Handy DE, Stanton RC, Pitt B, Loscalzo J. Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med 2007;13:189-197.
7. Nakamura T, Kataoka K, Fukuda M, Nako H, Tokutomi Y, Dong YF, Ichijo H, Ogawa H, Kim-Mitsuyama S. Critical role of apoptosis signal-regulating kinase 1 in aldosterone/salt-induced cardiac inflammation and fibrosis. Hypertension 2009; 54:544-551.
8. Rocha R, Rudolph AE, Frierdich GE, Nachowiak DA, Kekec BK, Blomme EA, McMahon EG, Delyani JA. Aldosterone induces a vascular inflammatory pheno-type in the rat heart. Am J Physiol Heart Circ Physiol 2002;283:H1802-H1810.
9. Blanco-Rivero J, Cachofeiro V, Lahera V, ras-Lopez R, Marquez-Rodas I, Salaices M, Xavier FE, Ferrer M, Balfagon G. Participation of prostacyclin in endo-thelial dysfunction induced by aldosterone in normotensive and hypertensive rats. Hypertension 2005;46:107-112.
10. Garnier A, Bendall JK, Fuchs S, Escoubet B, Rochais F, Hoerter J, Nehme J, Ambroisine ML, De AN, Morineau G, d'Estienne P, Fischmeister R, Heymes C, Pinet F, Delcayre C. Cardiac specific increase in aldosterone production induces coronary dysfunction in aldosterone synthase-transgenic mice. Circulation 2004;110:1819-1825.
11. Endemann DH, Touyz RM, Iglarz M, Savoia C, Schiffrin EL. Eplerenone prevents salt-induced vascular remodeling and cardiac fibrosis in stroke-prone spontaneously hypertensive rats. Hypertension 2004;43:1252-1257.
12. Funder JW. Reconsidering the roles of the mineralocorticoid receptor. Hypertension 2009;53:286-290.
13. Gekle M, Grossmann C. Actions of aldosterone in the cardiovascular system: the good, the bad, and the ugly? Pflugers Arch 2009;458:231-246.
14. N'Gankam V, Uehlinger D, Dick B, Frey BM, Frey FJ. Increased cortisol metabolites and reduced activity of 11beta-hydroxysteroid dehydrogenase in patients on hemodialysis. Kidney Int 2002;61:1859-1866.
15. Henschkowski J, Stuck AE, Frey BM, Gillmann G, Dick B, Frey FJ, Mohaupt MG. Age-dependent decrease in 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2) activity in hypertensive patients. Am J Hypertens 2008;21: 644-649.
16. Wanner C, Krane V, Marz W, Olschewski M, Asmus HG, Kramer W, Kuhn KW, Kutemeyer H, Mann JF, Ruf G, Ritz E. Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics. Kidney Blood Press Res 2004; 27:259-266.
17. Hannemann A, Meisinger C, Bidlingmaier M, Doring A, Thorand B, Heier M, Belcredi P, Ladwig KH, Wallaschofski H, Friedrich N, Schipf S, Ludemann J, Rettig R, Peters J, Volzke H, Seissler J, Beuschlein F, Nauck M, Reincke M. Association of plasma aldosterone with the metabolic syndrome in two German populations. Eur J Endocrinol 2011;164:751-758.
18. Manolopoulou J, Bielohuby M, Caton SJ, Gomez-Sanchez CE, Renner-Mueller I, Wolf E, Lichtenauer UD, Beuschlein F, Hoeflich A, Bidlingmaier M. A highly sensitive immunofluorometric assay for the measurement of aldosterone in small sample volumes: validation in mouse serum. J Endocrinol 2008;196:215-224.
19. McGovern PG, Pankow JS, Shahar E, Doliszny KM, Folsom AR, Blackburn H, Luepker RV. Recent trends in acute coronary heart disease-mortality, morbidity, medical care, and risk factors. The Minnesota Heart Survey Investigators. N Engl J Med 1996;334:884-890.
20. Yeh RW, Sidney S, Chandra M, Sorel M, Selby JV, Go AS. Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med 2010;362: 2155-2165.
21. Collins AJ, Foley RN, Herzog C, Chavers BM, Gilbertson D, Ishani A, Kasiske BL, Liu J, Mau LW, McBean M, Murray A, St PW, Guo H, Li Q, Li S, Li S, Peng Y, Qiu Y, Roberts T, Skeans M, Snyder J, Solid C, Wang C, Weinhandl E, Zaun D, Arko C, Chen SC, Dalleska F, Daniels F, Dunning S, Ebben J, Frazier E, Hanzlik C, Johnson R, Sheets D, Wang X, Forrest B, Constantini E, Everson S, Eggers PW, Agodoa L. Excerpts from the US Renal Data System 2009 Annual Data Report. Am J Kidny Dis 2010;55(1 Suppl 1):S1-420, A426-427.
22. Herzog CA. Cardiac arrest in dialysis patients: approaches to alter an abysmal outcome. Kidney Int Suppl 2003;84:S197-S200.
23. Herzog CA, Asinger RW, Berger AK, Charytan DM, Diez J, Hart RG, Eckardt KU, Kasiske BL, McCullough PA, Passman RS, DeLoach SS, Pun PH, Ritz E. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2011;80:572-586.
24. Ritz E, Wanner C. The challenge of sudden death in dialysis patients. Clin J Am Soc Nephrol 2008;3:920-929.
25. Edwards NC, Steeds RP, Stewart PM, Ferro CJ, Townend JN. Effect of spironolac-tone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. J Am Coll Cardiol 2009;54:505-512.
26. Tomaschitz A, Pilz S, Ritz E, Grammer T, Drechsler C, Boehm BO, Marz W. Association of plasma aldosterone with cardiovascular mortality in patients with low estimated GFR: the Ludwigshafen Risk and Cardiovascular Health (LURIC) Study. Am J Kidny Dis 2011;57:403-414.
27. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348: 1309-1321.
28. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-717.
29. Lendeckel U, Dobrev D, Goette A. Aldosterone-receptor antagonism as a potential therapeutic option for atrial fibrillation. Br J Pharmacol 2010;159:1581-1583.
30. Raschi E, Boriani G, De Ponti F. Targeting the arrhythmogenic substrate in atrial fibrillation: focus on structural remodeling. Curr Drug Targets 2011;12:263-286.
31. Dartsch T, Fischer R, Gapelyuk A, Weiergraeber M, Ladage D, Schneider T, Schirdewan A, Reuter H, Mueller-Ehmsen J, Zobel C. Aldosterone induces electrical remodeling independent of hypertension. Int J Cardiol. Advance Access published July 18, 2011, doi:10.1016/j.ijcard.2011.06.100.
32. Tomaschitz A, Pilz S, Ritz E, Meinitzer A, Boehm BO, Marz W. Plasma aldosterone levels are associated with increased cardiovascular mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Eur Heart J 2010;31:1237-1247.
33. Luft FC. Connecting the renin-angiotensin-aldosterone system with sudden death. J Mol Med (Berl) 2011;89:631-633.
34. Amann K, Ritz E. Cardiac disease in chronic uremia: pathophysiology. Adv Ren Replace Ther 1997;4:212-224.
35. Briet M, Schiffrin EL. Aldosterone: effects on the kidney and cardiovascular system. Nat Rev Nephrol 2010;6:261-273.
36. Young MJ, Rickard AJ. Mechanisms of mineralocorticoid salt-induced hypertension and cardiac fibrosis. Mol Cell Endocrinol 2012;350:248-255.
37. Rautureau Y, Paradis P, Schiffrin EL. Cross-talk between aldosterone and angio-tensin signaling in vascular smooth muscle cells. Steroids 2011;76:834-839.
38. Waanders F, de Vries LV, van Goor H, Hillebrands JL, Laverman GD, Bakker SJ, Navis G. Aldosterone, from (patho)physiology to treatment in cardiovascular and renal damage. Curr Vasc Pharmacol 2011;9:594-605.
39. Gilbert KC, Brown NJ. Aldosterone and inflammation. Curr Opin Endocrinol Diabetes Obes 2010;17:199-204.
40. Krug AW, Allenhofer L, Monticone R, Spinetti G, Gekle M, Wang M, Lakatta EG. Elevated mineralocorticoid receptor activity in aged rat vascular smooth muscle cells promotes a proinflammatory phenotype via extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase and epidermal growth factor receptor-dependent pathways. Hypertension 2010;55:1476-1483.
41. Weir RA, Tsorlalis IK, Steedman T, Dargie HJ, Fraser R, McMurray JJ, Connell JM. Aldosterone and cortisol predict medium-term left ventricular remodelling following myocardial infarction. Eur J Heart Fail 2011;13:1305-1313.
42. Yamaji M, Tsutamoto T, Kawahara C, Nishiyama K, Yamamoto T, Fujii M, Horie M. Serum cortisol as a useful predictor of cardiac events in patients with chronic heart failure: the impact of oxidative stress. Circ Heart Fail 2009;2:608-615.
43. Guder G, Bauersachs J, Frantz S, Weismann D, Allolio B, Ertl G, Angermann CE, Stork S. Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation 2007;115:1754-1761.
44. Chua D, Lo A, Lo C. Spironolactone use in heart failure patients with end-stage renal disease on hemodialysis: is it safe? Clin Cardiol 2010;33:604-608.
45. Matsumoto Y, Kageyama S, Yakushigawa T, Arihara K, Sugiyama T, Mori Y, Sugiyama H, Ohmura H, Shio N. Long-term low-dose spironolactone therapy is safe in oligoanuric hemodialysis patients. Cardiology 2009;114:32-38.
46. Vukusich A, Kunstmann S, Varela C, Gainza D, Bravo S, Sepulveda D, Cavada G, Michea L, Marusic ET. A randomized, double-blind, placebo-controlled trial of spironolactone on carotid intima-media thickness in nondiabetic hemodialysis patients. Clin J Am Soc Nephrol 2010;5:1380-1387.
47. McGill RL, Biederman RW, Getts RT, Hazlett SM, Sharma SB, Duran J, Brandys DE, Sysak JC, Sureshkumar KK, Sandroni SE, Marcus RJ. Cardiac magnetic resonance imaging in hemodialysis patients. J Nephrol. 2009;22: 367-372.
48. Taheri S, Mortazavi M, Shahidi S, Pourmoghadas A, Garakyaraghi M, Seirafian S, Eshaghian A, Ghassami M. Spironolactone in chronic hemodialysis patients improves cardiac function. Saudi J Kidney Dis Transpl 2009;20:392-397.
49. Grande Villoria J, Macias Nunez JF, Miralles JM, De Castro del Pozo S, Tabernero Romo JM. Hyporeninemic hypoaldosteronism in diabetic patients with chronic renal failure. Am J Nephrol 1988;8:127-137.
50. Schirpenbach C, Seiler L, Maser-Gluth C, Beuschlein F, Reincke M, Bidlingmaier M. Automated chemiluminescence-immunoassay for aldosterone during dynamic testing: comparison to radioimmunoassays with and without extraction steps. Clin Chem 2006;52:1749-1755.